A Phase 1/2a Study of BMS-986178 Administered Alone and in Combination With Nivolumab or Ipilimumab in Advanced Solid Tumors

June 15, 2017

Sponsor

Bristol-Myers Squibb

Protocol Number

Bristol Myers Squibb CA012-004 (OX-40)

To Learn More Call

201-510-0910